Sandoz Offer For SyStemix Pending

16 June 1996

The unsolicited offer made by Sandoz of Switzerland to acquire all the shares of SyStemix that it does not already own for $17 per share (Marketletter June 3) is being considered by three independent members of the board of directors of SyStemix, according to the US company.

SyStemix also said that it has been informed of five stockholder suits with respect to the Sandoz proposal. The suits, each asking for class action status, were filed at the beginning of June in the Delaware Chancery Court. Sandoz, SyStemix, and the individual members of the SyStemix board are named as defendants.

The suits generally seek to join consummation of the Sandoz proposal on the grounds that the consideration to be paid to the public stockholders under the proposal is unfair and inadequate.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight